Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04020198 · ClinicalTrials.gov registry record
A Pilot Biomarker Study Assessing Alpha-synuclein Aggregates Across Biofluid Reservoirs in Patients With Synucleinopathies
A clinical trial, sponsored by Stony Brook University.
- Terminated
- Registry status
- 8
- Enrollment target
NCT04020198: Clinical Trial study, sponsored by Stony Brook University.
NCT04020198 is a clinical trial that was terminated before completion, run by Stony Brook University. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04020198 was terminated before completion, sponsored by Stony Brook University.
- TERMINATED
- Registry status
- 8 participants
- Enrollment target
Study Summary
This will be an observational study looking at clinical and biomarker characteristics in patients with Parkinson's Disease (PD), Multiple System Atrophy (MSA), Rapid Eye Movement Sleep Behavior Disorder (RBD), Normal Pressure Hydrocephalus and matched controls. Saliva, plasma, serum, urine, and cerebrospinal fluid (CSF) samples will be collected from participants.
Primary Outcome
Levels of misfolded alpha-synuclein in CSF, serum, plasma, saliva, and urine will be quantified using the protein misfolding cyclic amplification (PMCA) technology
Interventions
- OTHER Biomarker assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-01-15 |
| Est. Completion | 2022-10-19 |
Why NCT04020198 stopped before completion
NCT04020198 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Biomarker assay is the first listed.
NCT04020198 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04020198 about?
NCT04020198 is a clinical study titled "A Pilot Biomarker Study Assessing Alpha-synuclein Aggregates Across Biofluid Reservoirs in Patients With Synucleinopathies". This will be an observational study looking at clinical and biomarker characteristics in patients with Parkinson's Disease (PD), Multiple System Atrophy (MSA), Rapid Eye Movement Sleep Behavior Disorder (RBD), Normal Pressure Hydrocephalus and matched controls. Saliva, plasma, serum, urine, and cere...
What is the current status of trial NCT04020198?
This trial is currently terminated. The enrollment target is 8 participants. The study started on 2020-01-15. Estimated completion is 2022-10-19.
What interventions are being tested in trial NCT04020198?
The interventions under investigation include: Biomarker assay (OTHER).
Who is sponsoring clinical trial NCT04020198?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI